Patents by Inventor James R. Falsey
James R. Falsey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210346513Abstract: The present disclosure relates to a method of capping, reducing, and oxidizing cys-mAbs in order to provide homogenous material for subsequent conjugation reactions. The present method demonstrates robust ways to manufacture conjugates of cysteine-engineered antibodies that offer high yield and consistent product quality.Type: ApplicationFiled: August 3, 2018Publication date: November 11, 2021Applicant: AMGEN INC.Inventors: Michal ACHMATOWICZ, Dante ROMANINI, James R. FALSEY, Bradley J. HERBERICH, Oliver R. THIEL
-
Publication number: 20210154318Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.Type: ApplicationFiled: January 15, 2021Publication date: May 27, 2021Inventors: Yuan CHENG, Chawita NETIROJJANAKUL, Jerry Ryan HOLDER, Bin WU, James R. FALSEY, Bradley J. HERBERICH, Kelvin SHAM, Leslie P. MIRANDA, Shu-Chen LU, Murielle VENIENT-ELLISON, Shanaka STANISLAUS, Junming YIE, Jing XU
-
Patent number: 10905772Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.Type: GrantFiled: January 16, 2018Date of Patent: February 2, 2021Assignee: Amgen Inc.Inventors: Yuan Cheng, Chawita Netirojjanakul, Jerry Ryan Holder, Bin Wu, James R. Falsey, Bradley J. Herberich, Kelvin Sham, Leslie P. Miranda, Shu-Chen Lu, Murielle M. Veniant-Ellison, Shanaka Stanislaus, Junming Yie, Jing Xu
-
Patent number: 10344060Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: GrantFiled: March 12, 2014Date of Patent: July 9, 2019Assignee: AMGEN INC.Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda, Kaustav Biswas, Bin Wu, Kelvin Sham, Jason C. Long
-
Publication number: 20180311372Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.Type: ApplicationFiled: January 16, 2018Publication date: November 1, 2018Applicant: AMGEN INC.Inventors: Yuan CHENG, Chawita NETIROJJANAKUL, Jerry Ryan HOLDER, Bin WU, James R. FALSEY, Bradley J. HERBERICH, Kelvin SHAM, Leslie P. MIRANDA, Shu-Chen LU, Murielle VENIANT-ELLISON, Shanaka STANISLAUS, Junming YIE, Jing XU
-
Patent number: 9636418Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: GrantFiled: March 12, 2014Date of Patent: May 2, 2017Assignee: AMGEN INC.Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda
-
Publication number: 20160024159Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: January 28, 2016Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Jerry Ryan HOLDER, Malgorzata WANSKA, Christopher M. TEGLEY, James R. FALSEY, Elizabeth M. DOHERTY, Leslie P. MIRANDA, Kaustav BISWAS, Bin WU, Kelvin SHAM, Jason C. LONG
-
Publication number: 20150023988Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: January 22, 2015Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Jerry Ryan HOLDER, Malgorzata WANSKA, Christopher M. TEGLEY, James R. FALSEY, Elizabeth M. DOHERTY, Leslie P. MIRANDA
-
Patent number: 8759532Abstract: Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.Type: GrantFiled: November 14, 2012Date of Patent: June 24, 2014Assignee: Amgen Inc.Inventors: Jennifer R. Allen, Kaustav Biswas, Frank Chavez, Jr., Ning Chen, Frenel Fils De Morin, James R. Falsey, Michael J. Frohn, Paul E. Harrington, Daniel B. Home, Essa Hu Harrington, Matthew R. Kaller, Roxanne K. Kunz, Holger Monenschein, Thomas T. Nguyen, Alexander J. Pickrell, Andreas Reichelt, Shannon Rumfelt, Robert M. Rzasa, Kelvin Sham, Guomin Yao
-
Patent number: 8716281Abstract: The present invention describes pyrimidine compounds of Formula I that are useful as anaplastic lymphoma kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: GrantFiled: May 4, 2011Date of Patent: May 6, 2014Assignee: Amgen Inc.Inventors: Marian C. Bryan, Alan C. Cheng, Elizabeth M. Doherty, James R. Falsey, Ingrid M. Fellows, Joseph L. Kim, Richard T. Lewis, Michele H. Potashman, Douglas A. Whittington
-
Patent number: 8637500Abstract: Pyridine and pyrimidine compounds: or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, R6, R7, X1, X2, X3, X4, X5, X6, X7, X8, and Y are as defined in the specification; or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2, and ring A are as defined in the specification; and or a pharmaceutically acceptable salt thereof, wherein m, n, y, R2, R3, R4, R5, R6, R7, R9, X1, X2, and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.Type: GrantFiled: December 16, 2009Date of Patent: January 28, 2014Assignee: Amgen Inc.Inventors: Jennifer R. Allen, Ning Chen, James R. Falsey, Michael J. Frohn, Paul E. Harrington, Essa Hu Harrington, Matthew R. Kaller, Roxanne K. Kunz, Thomas T. Nguyen, Alexander J. Pickrell, Andreas Reichelt, Shannon Rumfelt, Robert M. Rzasa, Kelvin Sham, Aaron C. Siegmund, Guomin Yao
-
Patent number: 8497269Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A4, L, R1, R2, R3, R5 and m are as defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, ankylosing spondylitis, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.Type: GrantFiled: October 7, 2009Date of Patent: July 30, 2013Assignee: Amgen Inc.Inventors: Andrew Tasker, James R. Falsey, Robert M. Rzasa, Bradley J. Herberich, Dawei Zhang
-
Publication number: 20130158019Abstract: Compounds of Formula I are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.Type: ApplicationFiled: May 4, 2011Publication date: June 20, 2013Applicant: AMGEN INC.Inventors: Marian C. Bryan, Alan C. Cheng, Elizabeth M. Doherty, James R. Falsey, Ingrid M. Fellows, Joseph L. Kim, Richard T. Lewis, Michele H. Potashman, Douglas A. Whittington
-
Publication number: 20130079325Abstract: Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.Type: ApplicationFiled: November 14, 2012Publication date: March 28, 2013Inventors: Jennifer R. Allen, Biswas Kaustav, Frank Chavez, Ning Chen, Frenel Fils De Morin, James R. Falsey, Michael J. Frohn, Paul E. Harrington, Daniel B. Horne, Essa Hu Harrington, Matthew R. Kaller, Roxanne Kunz, Holger Monenschein, Thomas T. Nguyen, Alexander J. Pickrell, Andreas Reichelt, Shannon Rumfelt, Robert M. Rzasa, Kelvin Sham, Guomin Yao
-
Patent number: 8318718Abstract: Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.Type: GrantFiled: November 16, 2009Date of Patent: November 27, 2012Assignee: Amgen Inc.Inventors: Jennifer R. Allen, Biswas Kaustav, Frank Chavez, Ning Chen, Frenel Fils De Morin, James R. Falsey, Michael J. Frohn, Paul E. Harrington, Daniel B. Horne, Essa Hu Harrington, Matthew R. Kaller, Roxanne Kunz, Holger Monenschein, Thomas T. Nguyen, Alexander J. Pickrell, Andreas Reichelt, Shannon Rumfelt, Robert M. Rzasa, Kelvin Sham, Guomin Yao
-
Patent number: 8247409Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.Type: GrantFiled: November 11, 2009Date of Patent: August 21, 2012Assignee: Amgen Inc.Inventors: Fang-Tsao Hong, James R. Falsey, Seifu Tadesse, Andrew Tasker
-
Publication number: 20120040983Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A4, L, R1, R2, R3, R5 and m are as defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, ankylosing spondylitis, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.Type: ApplicationFiled: October 7, 2009Publication date: February 16, 2012Applicant: Amgen Inc.Inventors: Andrew Tasker, James R. Falsey, Robert M. Rzasa, Bradley J. Herberich, Dawei Zhang
-
Publication number: 20110118234Abstract: The present invention provides compounds Formula (I) that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.Type: ApplicationFiled: May 4, 2009Publication date: May 19, 2011Inventors: Kaustav Biswas, Jian J. Chen, James R. Falsey, Vijay Keshav Gore, Qingyian Liu, Vu Van Ma, Stephanie J. Mercede, Robert M. Rzasa, Christopher M. Tegley, Jiawang Zhu
-
Patent number: 7897619Abstract: The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.Type: GrantFiled: July 16, 2008Date of Patent: March 1, 2011Assignee: Amgen Inc.Inventors: Qingping Zeng, Dawei Zhang, Guomin Yao, George E. Wohlhieter, Xianghong Wang, James Rider, Andreas Reichelt, Holger Monenschein, Fang-Tsao Hong, James R. Falsey, Celia Dominguez, Matthew P. Bourbeau, John G. Allen
-
Patent number: 7745449Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.Type: GrantFiled: April 23, 2007Date of Patent: June 29, 2010Assignee: Amgen Inc.Inventors: Fang-Tsao Hong, James R. Falsey, Robert M. Rzasa, Seifu Tadesse, Andrew Tasker